Kalkine has a fully transformed New Avatar.
Last update at 2025-07-03T11:45:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Is Holcim Ltd Unsponsored ADR (HCMLY) Outperforming Other Construction Stocks This Year?
Tue 22 Apr 25, 01:40 PMWhat Trump's tariffs could mean for UK mortgage rates
Thu 03 Apr 25, 01:03 PMWith 82% institutional ownership, Persimmon Plc (LON:PSN) is a favorite amongst the big guns
Wed 26 Mar 25, 01:35 PMPSMMY vs. NVR: Which Stock Is the Better Value Option?
Tue 25 Mar 25, 03:40 PMFirst-time buyer mortgage sales in the UK at lowest level in a decade
Tue 18 Mar 25, 01:15 PMPersimmon Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Wed 12 Mar 25, 01:07 PMPersimmon raises building targets amid signals of housing market recovery
Tue 11 Mar 25, 09:06 AMPersimmon (LON:PSN) Might Be Having Difficulty Using Its Capital Effectively
Wed 26 Feb 25, 10:10 AMFour in five homebuyers to pay more stamp duty from April
Wed 19 Feb 25, 06:00 AMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 730.70M | 966.80M | 783.80M | 1040.80M | 1090.80M |
Minority interest | - | - | - | - | - |
Net income | 561.00M | 787.20M | 638.40M | 848.80M | 886.40M |
Selling general administrative | - | - | - | 107.40M | 101.10M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 867.50M | 1083.80M | 894.40M | 1130.70M | 1179.90M |
Reconciled depreciation | 15.80M | 14.50M | 14.10M | 13.30M | 10.00M |
Ebit | 734.80M | 970.40M | 783.50M | 1029.40M | 1103.10M |
Ebitda | 750.60M | 984.90M | 806.50M | 1063.20M | 1113.10M |
Depreciation and amortization | 15.80M | 14.50M | 23.00M | 33.80M | 10.00M |
Non operating income net other | - | - | - | - | - |
Operating income | 734.80M | 970.40M | 783.50M | 1029.40M | 1082.70M |
Other operating expenses | 3090.90M | 2650.00M | 2544.80M | 2620.00M | 2654.90M |
Interest expense | 4.10M | 3.60M | 8.60M | 9.10M | 12.30M |
Tax provision | 169.70M | 179.60M | 145.40M | 192.00M | 204.40M |
Interest income | 6.00M | 9.90M | 8.90M | 7.40M | 9.20M |
Net interest income | 5.80M | 6.30M | 0.30M | 11.40M | 8.10M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 169.70M | 179.60M | 145.40M | 192.00M | 204.40M |
Total revenue | 3815.80M | 3610.50M | 3328.30M | 3649.40M | 3737.60M |
Total operating expenses | 142.60M | 123.30M | 110.90M | 101.30M | 97.20M |
Cost of revenue | 2948.30M | 2526.70M | 2433.90M | 2518.70M | 2557.70M |
Total other income expense net | -4.10000M | -3.60000M | 0.30M | 11.40M | 8.10M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 561.00M | 787.20M | 638.40M | 848.80M | 886.40M |
Net income applicable to common shares | 561.00M | 787.20M | 638.40M | 848.80M | 886.40M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-06-30 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-06-30 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Total assets | - | 5034.10M | 4792.20M | 4623.10M | 4489.30M |
Intangible assets | - | 60.00M | 60.00M | 60.00M | 60.00M |
Earning assets | - | - | - | - | - |
Other current assets | - | 221.90M | 155.20M | 109.40M | 67.90M |
Total liab | - | 1594.80M | 1167.00M | 1104.70M | 1231.00M |
Total stockholder equity | - | 3439.30M | 3625.20M | 3518.40M | 3258.30M |
Deferred long term liab | - | - | - | - | - |
Other current liab | - | 142.10M | 78.20M | 80.50M | 84.50M |
Common stock | - | 31.90M | 31.90M | 31.90M | 31.90M |
Capital stock | - | 31.90M | 31.90M | 31.90M | 31.90M |
Retained earnings | - | 2868.50M | 3055.10M | 2950.90M | 2693.90M |
Other liab | - | 492.40M | 273.00M | 220.40M | 225.90M |
Good will | - | 113.00M | 115.60M | 121.80M | 126.10M |
Other assets | - | 195.80M | 194.80M | 104.00M | 150.50M |
Cash | - | 861.60M | 1246.60M | 1234.10M | 843.90M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | - | 1091.50M | 885.20M | 874.70M | 996.20M |
Current deferred revenue | - | - | - | - | - |
Net debt | - | -861.60000M | -1246.60000M | -1234.10000M | -843.90000M |
Short term debt | - | - | - | 285.50M | - |
Short long term debt | - | - | - | - | - |
Short long term debt total | - | - | - | - | - |
Other stockholder equity | - | 538.90M | 538.20M | 535.60M | 532.50M |
Property plant equipment | - | 118.60M | 99.00M | 90.40M | 82.00M |
Total current assets | - | 4546.40M | 4322.50M | 4244.80M | 4068.60M |
Long term investments | - | - | - | - | 2.10M |
Net tangible assets | - | 3266.30M | 3449.60M | 3336.60M | 3072.20M |
Short term investments | - | - | - | - | - |
Net receivables | - | 153.70M | 155.20M | 102.80M | 61.90M |
Long term debt | - | - | - | - | - |
Inventory | - | 3462.90M | 2920.70M | 2901.30M | 3156.80M |
Accounts payable | - | 949.40M | 807.00M | 794.20M | 911.70M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | - | - | - | - | -96.20000M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | 31.90M | 31.90M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | - | 185.60M | 185.40M | 98.40M | 146.00M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | - | 487.70M | 469.70M | 378.30M | 420.70M |
Capital lease obligations | - | - | - | - | - |
Long term debt total | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | -29.80000M | 1.80M | -18.10000M | 0.90M | 0.90M |
Change to liabilities | 141.10M | 37.40M | -116.90000M | -225.60000M | -82.70000M |
Total cashflows from investing activities | -29.80000M | -18.20000M | -18.10000M | -25.90000M | -15.00000M |
Net borrowings | -3.30000M | -3.30000M | -3.60000M | -3.80000M | -3.80000M |
Total cash from financing activities | -757.50000M | -754.10000M | -357.20000M | -798.30000M | -893.90000M |
Change to operating activities | 13.30M | 18.90M | 16.40M | 31.40M | 41.60M |
Net income | 561.00M | 787.20M | 638.40M | 848.80M | 886.40M |
Change in cash | -385.00000M | 12.50M | 390.20M | -204.20000M | -254.60000M |
Begin period cash flow | 1246.60M | 1234.10M | 843.90M | 1048.10M | 1302.70M |
End period cash flow | 861.60M | 1246.60M | 1234.10M | 843.90M | 1048.10M |
Total cash from operating activities | 402.30M | 784.80M | 765.50M | 620.00M | 654.30M |
Issuance of capital stock | 0.70M | 2.60M | 0.70M | 43.30M | 157.10M |
Depreciation | 15.80M | 14.50M | 14.10M | 13.30M | 10.00M |
Other cashflows from investing activities | - | - | 0.80M | 1.60M | 0.50M |
Dividends paid | 750.10M | 749.60M | 350.70M | 747.80M | 732.30M |
Change to inventory | -532.50000M | -9.80000M | 265.00M | -87.70000M | -225.50000M |
Change to account receivables | -81.10000M | -59.50000M | -45.80000M | 6.30M | -26.70000M |
Sale purchase of stock | -0.70000M | - | 3.10M | 3.90M | -1.30000M |
Other cashflows from financing activities | -7.40000M | -7.10000M | -7.20000M | -7.20000M | -3.20000M |
Change to netincome | 284.70M | -3.90000M | -5.70000M | 33.50M | 51.20M |
Capital expenditures | 30.50M | 20.90M | 18.90M | 27.50M | 15.50M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | -459.20000M | -13.00000M | 118.70M | -275.60000M | -293.30000M |
Stock based compensation | 9.00M | 6.40M | 6.40M | 3.70M | 7.90M |
Other non cash items | 275.70M | -8.10000M | -9.00000M | -11.30000M | -6.40000M |
Free cash flow | 371.80M | 763.90M | 746.60M | 592.50M | 638.80M |
Sector: Consumer Cyclical Industry: Residential Construction
Company | Change (GBX) | Price (GBX) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
PSN Persimmon PLC |
13.32 1.10% | 1223.83 | 13.61 | 16.37 | 1.33 | 1.32 | 1.23 | 8.71 |
TW Taylor Wimpey PLC |
1.20 1.06% | 114.50 | 9.07 | 15.41 | 1.28 | 1.14 | 1.13 | 5.85 |
BKG The Berkeley Group Holdings plc |
92.00 2.56% | 3692.00 | 11.34 | 13.26 | 1.99 | 1.49 | 1.84 | 7.23 |
VTY Vistry Group PLC |
17.80 2.88% | 635.80 | 12.94 | 9.63 | 1.00 | 0.95 | 1.12 | 10.16 |
BWY Bellway PLC |
44.00 1.68% | 2656.00 | 8.74 | 20.92 | 0.90 | 0.89 | 0.84 | 5.47 |
Persimmon Plc, together with its subsidiaries, operates as a house builder in the United Kingdom. The company offers family housing under the Persimmon Homes brand name; housing under the Charles Church brand name; and social housing under the Westbury Partnerships brand name. It also provides broadband services under the FibreNest brand; and timber frame, insulated wall panels, and roof cassettes under the brand Space4. Further, it offers concrete bricks and roof tile. Persimmon Plc was founded in 1972 and is headquartered in York, the United Kingdom.
1330 O?Brien Drive, Menlo Park, CA, United States, 94025
Name | Title | Year Born |
---|---|---|
Mr. John Stephen West | Co-Founder, CEO, Pres & Director | 1957 |
Mr. Aaron L. Tachibana | Sr. VP & CFO | 1961 |
Dr. Richard Chen M.D., M.S., MS | Sr. VP of R&D and Chief Medical Officer | 1971 |
Dr. Russ B. Altman M.D., Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | NA |
Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | 1972 |
Dr. Atul Butte | Co-Founder and Member of Clinical & Scientific Advisory Board | NA |
Dr. Michael Snyder Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | NA |
Ms. Carol J. Tillis | VP of Fin. & Admin. | NA |
Mr. Stephen M. Moore J.D. | VP, Gen. Counsel & Corp. Sec. | 1972 |
Mr. Michael J Fitzpatrick | VP of Worldwide Sales | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.